#AANAM – Investigational DM1 Therapy Shows Promise

#AANAM – Investigational DM1 Therapy Shows Promise

292243

#AANAM – Investigational DM1 Therapy Shows Promise

Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. An investigational therapy called AOC-1001 decreased levels of the toxic RNA molecule that causes myotonic dystrophy type 1 (DM1) in cell and animal models of the disease. Avidity Biosciences expects to start clinical studies testing the potential therapy later this year. The findings were shared…

You must be logged in to read/download the full post.